GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Silence Therapeutics PLC (OTCPK:SLNCF) » Definitions » Operating Margin %

Silence Therapeutics (Silence Therapeutics) Operating Margin % : -633.57% (As of Dec. 2023)


View and export this data going back to 2007. Start your Free Trial

What is Silence Therapeutics Operating Margin %?

Operating Margin % is calculated as Operating Income divided by its Revenue. Silence Therapeutics's Operating Income for the three months ended in Dec. 2023 was $-16.83 Mil. Silence Therapeutics's Revenue for the three months ended in Dec. 2023 was $2.66 Mil. Therefore, Silence Therapeutics's Operating Margin % for the quarter that ended in Dec. 2023 was -633.57%.

The historical rank and industry rank for Silence Therapeutics's Operating Margin % or its related term are showing as below:

SLNCF' s Operating Margin % Range Over the Past 10 Years
Min: -91861.9   Med: -1100.5   Max: -195.49
Current: -196.58


SLNCF's Operating Margin % is ranked worse than
51.84% of 1030 companies
in the Biotechnology industry
Industry Median: -173.23 vs SLNCF: -196.58

Silence Therapeutics's 5-Year Average Operating Margin % Growth Rate was 0.00% per year.

Silence Therapeutics's Operating Income for the three months ended in Dec. 2023 was $-16.83 Mil. Its Operating Income for the trailing twelve months (TTM) ended in Dec. 2023 was $-61.76 Mil.


Silence Therapeutics Operating Margin % Historical Data

The historical data trend for Silence Therapeutics's Operating Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Silence Therapeutics Operating Margin % Chart

Silence Therapeutics Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Operating Margin %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -9,311.25 -654.28 -369.03 -277.66 -195.49

Silence Therapeutics Quarterly Data
Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Operating Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -230.03 -106.82 -125.85 -453.86 -633.57

Competitive Comparison of Silence Therapeutics's Operating Margin %

For the Biotechnology subindustry, Silence Therapeutics's Operating Margin %, along with its competitors' market caps and Operating Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Silence Therapeutics's Operating Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Silence Therapeutics's Operating Margin % distribution charts can be found below:

* The bar in red indicates where Silence Therapeutics's Operating Margin % falls into.



Silence Therapeutics Operating Margin % Calculation

Operating Margin % - also known as operating income margin, operating profit margin and return on sales (ROS) - is the ratio of Operating Income divided by net sales or Revenue, usually presented in percent.

Silence Therapeutics's Operating Margin % for the fiscal year that ended in Dec. 2023 is calculated as

Operating Margin %=Operating Income (A: Dec. 2023 ) / Revenue (A: Dec. 2023 )
=-62.79 / 32.12
=-195.49 %

Silence Therapeutics's Operating Margin % for the quarter that ended in Dec. 2023 is calculated as

Operating Margin %=Operating Income (Q: Dec. 2023 ) / Revenue (Q: Dec. 2023 )
=-16.834 / 2.657
=-633.57 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Silence Therapeutics  (OTCPK:SLNCF) Operating Margin % Explanation

Just like Gross Margin %, it is important to see a company maintains its operating margin over time. Among the same industry, a company with higher operating margin is more efficient in its operation. It is also more stable during industry slowdown or recessions. Peter Lynch prefers those with higher margins than those with lower margins.


Be Aware

Operating Margin % can be manipulated by adjusting the rate of depreciation, depletion and amortization (DDA).

If a company is facing competition, its Operating Margin % may decline. Often the Operating Margin % declines well before the company's Revenue or even profit decline. Therefore, Operating Margin % is a very important indicator of whether the company is facing problems.

For instance, by 2012, Nokia (NOK)'s problems were well known and its stock had lost more than 90% of its market value since 2007. But Nokia’s Operating Margin % had already been in decline since 2002, although its Earnings per Share (Diluted) were still rising. Investors who paid attention to Operating Margin % would have avoided this huge loss. The same can be said for Research-in-Motion (RIMM).

Therefore, Operating Margin % is a very important screening filter for GuruFocus. GuruFocus's Buffett-Munger screener requires that the profit margin is either consistent or expanding. The Model Portfolio of the Buffett-Munger screener has outperformed the market every year since inception in 2009.


Silence Therapeutics Operating Margin % Related Terms

Thank you for viewing the detailed overview of Silence Therapeutics's Operating Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.


Silence Therapeutics (Silence Therapeutics) Business Description

Traded in Other Exchanges
Address
72 Hammersmith Road, London, GBR, W14 8TH
Silence Therapeutics PLC is a biotechnology company focused on discovering and developing novel molecules incorporating short-interfering ribonucleic acid. its pipeline products are; SLN360 therapy designed to temporarily block a specific gene's message that would otherwise trigger an unwanted effect. By silencing the LPA gene, the levels of Lp(a) are lowered, which in turn is expected to lower the risk of heart diseases, heart attacks, and strokes, and SLN124 therapy aims to temporarily silence TMPRSS6, a gene that prevents the liver from producing a particular hormone that controls iron levels in the body hepcidin. As hepcidin increases, iron levels in the blood are expected to decrease, which may increase the production of healthy red blood cells, thereby reducing anemia.